Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

PHASE3CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
HIV InfectionsStreptococcus Pneumoniae
Interventions
BIOLOGICAL

pneumococcal conjugate vaccine

"Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:~2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension."

BIOLOGICAL

pneumococcal polysaccharide vaccine

PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.

Trial Locations (6)

20307

Walter Reed Army Medical Center, Washington D.C.

20814

National Naval Medical Center, Bethesda

23708

Naval Medical Center Portsmouth, Portsmouth

78236

San Antonio Military Medical Center, Lackland Air Force Base

92134

Naval Medical Center San Diego, San Diego

96859

Tripler Army Medical Center, Tripler AMC

All Listed Sponsors
collaborator

Infectious Diseases Clinical Research Program

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

US Military HIV Research Program

NETWORK

collaborator

Uniformed Services University of the Health Sciences

FED

lead

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

NCT00622843 - Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting | Biotech Hunter | Biotech Hunter